– UK, Winsford – Advanced Medical Solutions Group plc (LON: AMS), the surgical and advanced wound care specialist company, today announced the appointment of Douglas Le Fort to its Board as an Independent Non-Executive Director, effective immediately.
“I am very pleased to welcome Douglas to the Board of AMS, who brings with him significant commercial experience, particularly during his time at ConvaTec, as well as sector expertise. He will be an extremely valuable addition to our Board as AMS looks to grow,” said Chairman, Board Peter Allen.
About Douglas Le Fort
Douglas Le Fort is a seasoned veteran in the medical and life science industry, with more than 20 years of senior executive leadership. He has expertise in business strategy, including commercial business execution, operational management, and M&A. He is currently an Operating Partner for Revival Healthcare Capital Partners, an investor in medical device and diagnostics businesses, as well as a Non-Executive Director at Trio Healthcare, a manufacturer of ostomy products. Most recently, he was CEO of MedTrade Products, a wound-care products business, and before that served in various senior executive roles at ConvaTec Group plc, including five years on the Executive Committee for the Group. At ConvaTec, he was SVP for Corporate Development, and before that Vice President and General Manager with P&L responsibility for the global Ostomy business.
He has an MBA from Henley Management College and is a Chartered Management Accountant.
Douglas Le Fort said: “I have been watching AMS’s progress closely during my career and am very excited to be joining the team at such a high-quality Company. Alongside the rest of the Board, my focus will be on supporting AMS’s growth strategy and providing strategic advice as the business builds on its position in the UK and internationally.”
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, hemostats, and internal fixation devices, which it markets under its brands LiquiBand, RESORBA, and LiquiBandFix8. AMS also supplies wound care dressings such as silver alginates, alginates, and foams through its ActivHeal brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a leading coater and converter of materials predominately for woundcare and bio-diagnostics products based in the UK.
AMS’s products, manufactured in the UK, Germany, France, Israel, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic, and Russia. The Group has R&D innovation hubs in the UK, Germany, France, and Israel. Established in 1991, the Group has more than 700 employees.
For more information: https://www.admedsol.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.